Database Query Results : , , ERK

ERK, ERK signaling: Click to Expand ⟱
Source:
Type:
MAPK3 (ERK1)
ERK proteins are kinases that activate other proteins by adding a phosphate group. An overactivation of these proteins causes the cell cycle to stop.
The extracellular signal-regulated kinase (ERK) signaling pathway is a crucial component of the mitogen-activated protein kinase (MAPK) signaling cascade, which plays a significant role in regulating various cellular processes, including proliferation, differentiation, and survival. high levels of phosphorylated ERK (p-ERK) in tumor samples may indicate active ERK signaling and could correlate with aggressive tumor behavior

EEk singaling is frequently activated and is often associated with aggressive tumor behavior, treatment resistance, and poor outcomes.
Scientific Papers found: Click to Expand⟱
2662- AL,    Allicin inhibits tubular epithelial-myofibroblast transdifferentiation under high glucose conditions in vitro
- in-vitro, Nor, HK-2
*α-SMA↓, *Vim↓, *COL1↓, *E-cadherin↑, *TGF-β1↓, *p‑ERK↓, *EMT↓,
1253- aLinA,    The Antitumor Effects of α-Linolenic Acid
- Review, NA, NA
PPARγ↑, COX2↓, E6↓, E7↓, P53↑, p‑ERK↓, p38↓, lipid-P↑, ROS⇅, MPT↑, MMP↓, Cyt‑c↑, Casp↑, iNOS↓, NO↓, Casp3↑, Bcl-2↓, Hif1a↓, FASN↓, CRP↓, IL6↓, IL1β↓, IFN-γ↓, TNF-α↓, Twist↓, VEGF↓, MMP2↓, MMP9↓,
1093- And,    Andrographolide attenuates epithelial‐mesenchymal transition induced by TGF‐β1 in alveolar epithelial cells
- in-vitro, Lung, A549
TGF-β↓, TumCMig↓, MMP2↓, MMP9↓, ECM/TCF↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓, p‑ERK↓, ROS↓, NOX4↓, SOD2↑, SIRT1↑, FOXO3↑,
1539- Api,  LT,    Dietary flavones counteract phorbol 12-myristate 13-acetate-induced SREBP-2 processing in hepatic cells
- in-vitro, Liver, HepG2
SREBP2↓, eff↑, p‑MEK↓, p‑ERK↓,
1545- Api,    The Potential Role of Apigenin in Cancer Prevention and Treatment
- Review, NA, NA
TNF-α↓, IL6↓, IL1α↓, P53↑, Bcl-xL↓, Bcl-2↓, BAX↑, Hif1a↓, VEGF↓, TumCCA↑, DNAdam↑, Apoptosis↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK1↓, PI3K↓, Akt↓, mTOR↓, IKKα↓, ERK↓, p‑Akt↓, p‑P70S6K↓, p‑S6↓, p‑ERK↓, p‑P90RSK↑, STAT3↓, MMP2↓, MMP9↓, TumCP↓, TumCMig↓, TumCI↓, Wnt/(β-catenin)↓,
2633- Api,    Apigenin induces ROS-dependent apoptosis and ER stress in human endometriosis cells
- in-vitro, EC, NA
TumCP↓, TumCCA↑, MMP↓, Ca+2↑, BAX↑, Cyt‑c↑, ROS↑, lipid-P↑, ER Stress↑, UPR↑, p‑ERK↓, ERK↓, JNK↑,
3392- ART/DHA,    Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways
- in-vitro, Nor, Hep3B - in-vivo, NA, NA
*Inflam↓, *NF-kB↓, *ROS↓, *p‑p38↓, *p‑ERK↓,
1148- ART/DHA,    Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cδ/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages
- in-vitro, AML, THP1
MMP9↓, EMMPRIN↓, p‑PKCδ↓, p‑JNK↓, p‑p38↓, p‑ERK↓,
573- ART/DHA,    Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model
- vitro+vivo, NA, NA
p‑p38↓, p‑ERK↓, p‑CREB↓, p‑Chk2↓, p‑STAT5↓, p‑RSK↓, SOCS1↑, Apoptosis↑, Casp3↑,
4809- ASTX,    Astaxanthin Inhibits Proliferation of Human Gastric Cancer Cell Lines by Interrupting Cell Cycle Progression
- in-vitro, GC, AGS - in-vitro, GC, MKN45
tumCV↓, TumCP↓, TumCCA↑, p‑ERK↓, p27↑, cycD1/CCND1↓, CDK4↓,
1242- BBM,    Berbamine Exerts Anti-Inflammatory Effects via Inhibition of NF-κB and MAPK Signaling Pathways
- in-vivo, Nor, NA
*Macrophages↓, *Neut↓, *p‑NF-kB↓, *p‑MAPK↓, *p‑JNK↓, *p‑ERK↓,
1395- BBR,    Analysis of the mechanism of berberine against stomach carcinoma based on network pharmacology and experimental validation
- in-vitro, GC, NA
Apoptosis↑, ROS↑, MMP↓, ATP↓, AMPK↑, TP53↑, p‑MAPK↓, p‑ERK↓,
2758- BetA,    Betulinic Acid Attenuates Oxidative Stress in the Thymus Induced by Acute Exposure to T-2 Toxin via Regulation of the MAPK/Nrf2 Signaling Pathway
- in-vivo, Nor, NA
*ROS↓, *MDA↓, *SOD↑, *GSH↑, *p‑p38↓, *p‑JNK↓, *p‑ERK↓, *NRF2↑, *HO-1↑, *MAPK↓, *heparanase↑, *antiOx↑,
726- Bor,    Redox Mechanisms Underlying the Cytostatic Effects of Boric Acid on Cancer Cells—An Issue Still Open
- Review, NA, NA
NAD↝, SAM-e↝, PSA↓, IGF-1↓, Cyc↓, P21↓, p‑MEK↓, p‑ERK↓, ROS↑, SOD↓, Catalase↓, MDA↑, GSH↓, IL1↓, IL6↓, TNF-α↓, BRAF↝, MAPK↝, PTEN↝, PI3K/Akt↝, eIF2α↑, ATF4↑, ATF6↑, NRF2↑, BAX↑, BID↑, Casp3↑, Casp9↑, Bcl-2↓, Bcl-xL↓,
2767- Bos,    The potential role of boswellic acids in cancer prevention and treatment
- Review, Var, NA
*Inflam↓, AntiCan↑, *MAPK↑, *Ca+2↝, p‑ERK↓, TumCI↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p‑RB1↓, *NF-kB↓, *TNF-α↓, NF-kB↓, IKKα↓, MCP1↓, IL1α↓, MIP2↓, VEGF↓, Tf↓, COX2↓, MMP9↓, CXCR4↓, VEGF↓, eff↑, PPARα↓, lipid-P?, STAT3↓, TOP1↓, TOP2↑, 5HT↓, p‑PDGFR-BB↓, PDGF↓, AR↓, DR5↑, angioG↓, DR4↑, Casp3↑, Casp8↑, cl‑PARP↑, eff↑, chemoPv↑, Wnt↓, β-catenin/ZEB1↓, ascitic↓, Let-7↑, miR-200b↑, eff↑, MMP1↓, MMP2↓, eff↑, BioAv↓, BioAv↑, Half-Life↓, toxicity↓, Dose↑, BioAv↑, ChemoSen↑,
2776- Bos,    Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities
- Review, Var, NA
*5LO↓, *TNF-α↓, *MMP3↓, *COX1↓, *COX2↓, *PGE2↓, *Th2↑, *Catalase↑, *SOD↑, *NO↑, *PGE2↑, *IL1β↓, *IL6↓, *Th1 response↓, *Th2↑, *iNOS↓, *NO↓, *p‑JNK↓, *p38↓, GutMicro↑, p‑Akt↓, GSK‐3β↓, cycD1/CCND1↓, Akt↓, STAT3↓, CSCs↓, AR↓, P21↑, DR5↑, CHOP↑, Casp3↑, Casp8↑, cl‑PARP↑, DNAdam↑, p‑RB1↓, FOXM1↓, TOP2↓, CDC25↓, p‑CDK1↓, p‑ERK↓, MMP9↓, VEGF↓, angioG↓, ROS↑, Cyt‑c↑, AIF↑, Diablo↑, survivin↓, ICAD↓, ChemoSen↑, SOX9↓, ER Stress↑, GRP78/BiP↑, cal2↓, AMPK↓, mTOR↓, ROS↓,
1587- Citrate,    ATP citrate lyase: A central metabolic enzyme in cancer
- Review, NA, NA
ACLY↓, other↓, PFK1↓, ATP↓, PFK2↓, Mcl-1↓, Casp3↑, Casp2↑, Casp9↑, IGF-1R↓, PI3K↓, Akt↓, p‑Akt↓, p‑ERK↓, PTEN↑, Snail↓, E-cadherin↑, ChemoSen↑,
155- CUR,    Osteopontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells
- in-vitro, Pca, PC3
p‑ERK↓, VEGF↓, angioS↑,
437- CUR,    Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids
- vitro+vivo, CRC, TCO1 - vitro+vivo, CRC, TCO2
cycD1/CCND1↓, cMyc↓, p‑ERK↓, CD44↓, CD133↓, LGR5↓, TumCCA↑, TumVol↓, CSCs↓,
473- CUR,    Curcumin inhibits epithelial-mesenchymal transition in oral cancer cells via c-Met blockade
- in-vitro, Oral, HSC4 - in-vitro, Oral, Ca9-22
Vim↓, p‑cMET↓, p‑ERK↓, pro‑MMP9↓, E-cadherin↑,
485- CUR,  PDT,    Red Light Combined with Blue Light Irradiation Regulates Proliferation and Apoptosis in Skin Keratinocytes in Combination with Low Concentrations of Curcumin
- in-vitro, Melanoma, NA
NF-kB↓, Casp8↑, Casp9↑, p‑Akt↓, p‑ERK↓,
1443- Deg,    Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-435 - in-vitro, BC, BT549
EGFR↓, Akt↓, p‑ERK↓, NF-kB↓, p‑STAT3↓, survivin↓, Myc↓, TumCG↓, cMET↓,
1446- Deg,    Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells
- in-vitro, BC, 4T1
cMET↓, p‑ERK↓, p‑Akt↓, TumCMig↓, TumCG↓, Weight∅, *toxicity∅, Hif1a↓, TumMeta↓,
1109- DHA,    DHA inhibits Gremlin-1-induced epithelial-to-mesenchymal transition via ERK suppression in human breast cancer cells
- in-vitro, BC, NA
GREM1↓, TumCMig↓, p‑ERK↓, EMT↓,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
1325- EMD,  PacT,    Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo
- vitro+vivo, Lung, A549
TumCP↓, Apoptosis↑, BAX↑, Casp3↑, Bcl-2↓, p‑Akt↓, p‑ERK↓, ChemoSideEff∅, ChemoSen↑,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,
1091- GA,    Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells
- in-vitro, Cerv, HeLa - in-vitro, Cerv, HTB-35
tumCV↓, TumCP↓, ADAM17↓, EGFR↓, p‑Akt↓, p‑ERK↓,
1118- Ge,    Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF- β Signaling Pathway
- in-vitro, Bladder, T24 - in-vitro, Bladder, 5637
TumCMig↓, TumCI↓, MMP2↓, MMP9↓, EMT↓, N-cadherin↓, Vim↓, Slug↓, E-cadherin↑, ZO-1↑, p‑SMAD2↓, p‑SMAD3↓, p‑Akt↓, p‑ERK↓, p‑p38↓,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
2908- LT,    Luteolin attenuates neutrophilic oxidative stress and inflammatory arthritis by inhibiting Raf1 activity
- in-vitro, Arthritis, NA
*ROS↓, *p‑ERK↓, *p‑MEK↓, *Raf↓,
4792- Lyco,    A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy
- Review, Var, NA
*AntiCan↑, *antiOx↑, Inflam↓, Wnt↓, β-catenin/ZEB1↓, *ROS↓, BioAv↑, ROS↓, Risk↓, PGE2↓, COX2↓, p‑ERK↓, P21↑, MMP7↓, MMP9↓, ChemoSen↑, eff↑,
1089- MAG,    Magnolol potently suppressed lipopolysaccharide-induced iNOS and COX-2 expression via downregulating MAPK and NF-κB signaling pathways
- in-vitro, AML, RAW264.7
p‑IκB↓, NF-kB↓, p‑ERK↓, p‑JNK↓, p‑PI3K↓, p‑Akt↓, iNOS↓, COX2↓,
4147- MF,    PEMFs Restore Mitochondrial and CREB/BDNF Signaling in Oxidatively Stressed PC12 Cells Targeting Neurodegeneration
- in-vitro, AD, PC12
*ROS↓, *Catalase↑, *MMP↑, *Casp3↓, *p‑ERK↓, *cAMP↑, *p‑CREB↑, *BDNF↑, *neuroP↑,
1141- Myr,    Myricetin: targeting signaling networks in cancer and its implication in chemotherapy
- Review, NA, NA
*PI3K↑, *Akt↑, p‑Akt↓, SIRT3↑, p‑ERK↓, p38↓, VEGF↓, MEK↓, MKK4↓, MMP9↓, Raf↓, F-actin↓, MMP2↓, COX2↓, BMP2↓, cycD1/CCND1↓, Bax:Bcl2↑, EMT↓, EGFR↓, TumAuto↑,
1674- PBG,  SDT,  HPT,    Study on the effect of a triple cancer treatment of propolis, thermal cycling-hyperthermia, and low-intensity ultrasound on PANC-1 cells
- in-vitro, PC, PANC1 - in-vitro, Nor, H6c7
tumCV↓, ROS↑, eff↑, Dose∅, selectivity↑, MMP↓, mtDam↑, cl‑PARP↑, p‑ERK↓, p‑JNK↑, p‑p38↑, eff↓, ChemoSen↑,
1059- PI,    Piperine Inhibits TGF-β Signaling Pathways and Disrupts EMT-Related Events in Human Lung Adenocarcinoma Cells
- in-vitro, Lung, A549 - in-vitro, BC, MDA-MB-231 - in-vitro, Liver, HepG2
EMT↓, p‑ERK↓, p‑SMAD2↓,
1164- PI,    Inhibition of T cell activation by the phytochemical piperine
- in-vitro, Nor, NA
*other↓, *CD25+↓, *IFN-γ↓, *IL2↓, *IL4↓, *IL17↓, *CD69↓, *CTLA-4↓, *p‑ERK↓, *IKKα↓,
2995- PL,    Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover
- in-vitro, Lung, H1975 - in-vitro, Lung, PC9 - in-vivo, NA, NA
Sp1/3/4↓, cMET↓, Apoptosis↑, Cyt‑c↑, p‑ERK↓, p‑Akt↓, TumCG↓,
81- QC,  EGCG,    Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea
- in-vivo, Pca, NA
COMT↓, MRP1↓, Ki-67↓, Bax:Bcl2↑, AR↓, Akt↓, p‑ERK↓, COMT↓, eff↑,
61- QC,    Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, ARPE-19
p‑PI3K↓, p‑Akt↓, p‑ERK↓, NF-kB↓, p38↓, ABCG2↓,
95- QC,    Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent
- in-vitro, Pca, PC3
p‑ERK↓, p‑STAT3↓, p‑Akt↓, N-cadherin↓, Vim↓, cycD1/CCND1↓, Snail↓, Slug↓, Twist↓, PCNA↓,
3353- QC,    Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells
- in-vitro, Oral, KON - in-vitro, Nor, MRC-5
tumCV↓, selectivity↑, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, TumMeta↓, Bcl-2↓, BAX↑, TIMP1↑, MMP2↓, MMP9↓, *Inflam↓, *neuroP↑, *cardioP↑, p38↓, MAPK↓, Twist↓, P21↓, cycD1/CCND1↓, Casp3↑, Casp9↑, p‑Akt↓, p‑ERK↓, CD44↓, CD24↓, ChemoSen↑, MMP↓, Cyt‑c↑, AIF↑, ROS↑, Ca+2↑, Hif1a↓, VEGF↓,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
3084- RES,    Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling
- in-vitro, BC, MCF-7 - in-vitro, BC, T47D
TumCP↓, EZH2↓, p‑ERK↓,
1090- SANG,    Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression.
- in-vitro, BC, MCF-7
MMP9↓, COX2↓, PGE2↓, NF-kB↓, AP-1↓, p‑Akt↓, p‑ERK↓, HO-1↑,
1499- SFN,    Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, FAK↓, p‑MEK↓, p‑ERK↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3304- SIL,    Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells
- in-vitro, GC, AGS - in-vivo, NA, NA
BAX↑, p‑JNK↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, Apoptosis↑, tumCV↓,
3305- SIL,    Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vivo, NA, NA
TumCP↓, tumCV↓, BAX↑, cl‑PARP↑, Casp9↑, p‑JNK↑, Bcl-2↓, p‑p38↓, p‑ERK↓, *toxicity∅, Dose↝, *hepatoP↑, Inflam↓, AntiCan↑,
3293- SIL,    Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer
- Review, Var, NA
hepatoP↑, TumMeta↓, Inflam↓, chemoP↑, radioP↑, Half-Life↝, *GSTs↑, p‑JNK↑, BAX↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, eff↑, TumCCA↑, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, Casp3↑, Casp9↑, eff↑, CXCR4↓, Dose↝,
3331- SIL,    The clinical anti-inflammatory effects and underlying mechanisms of silymarin
- Review, NA, NA
*Inflam↓, *NF-kB↓, *NLRP3↓, *COX2↓, *iNOS↓, *neuroP↑, *p‑ERK↓, *p38↓, *MAPK↓, *EGFR↓, *ROS↓, *lipid-P?, *5LO↓,
3319- SIL,    Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *BBB?, *tau↓, *NF-kB↓, *IL1β↓, *TNF-α↓, *IL4↓, *MAPK↓, *memory↑, *cognitive↑, *Aβ↓, *ROS↓, *lipid-P↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *AChE↓, *BChE↓, *p‑ERK↓, *p‑JNK↓, *p‑p38↓, *GutMicro↑, *COX2↓, *iNOS↓, *TLR4↓, *neuroP↑, *Strength↑, *AMPK↑, *MMP↑, *necrosis↓, *NRF2↑, *HO-1↑,
1276- SIL,    Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells
- in-vitro, BC, NA - in-vitro, Thyroid, NA
TumCMig↓, MMP9↓, p‑MEK↓, p‑ERK↓,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
3046- SK,    Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway
- in-vitro, Lung, A549
TumCP↓, TumCI↓, TumCMig↓, p‑ERK↓, ITGB1↓,
2211- SK,    Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways
- in-vivo, ostP, NA
*BMD↑, *p‑NF-kB↓, *p‑p50↓, *p‑p65↓, *p‑ERK↓, *p‑cJun↓, *p‑p38↓,
1133- SM,    Salvianolic Acid A, a Component of Salvia miltiorrhiza, Attenuates Endothelial-Mesenchymal Transition of HPAECs Induced by Hypoxia
- in-vitro, Nor, HPAECs
*ROS↓, *p‑Smad1↑, *p‑SMAD5↑, *SMAD2↓, *SMAD3↓, *p‑ERK↓, *p‑Cofilin↓,
309- SNP,    Interference of silver, gold, and iron oxide nanoparticles on epidermal growth factor signal transduction in epithelial cells
- in-vitro, NA, A431
ROS↑, Akt↓, p‑ERK↓,
382- SNP,    Investigation the apoptotic effect of silver nanoparticles (Ag-NPs) on MDA-MB 231 breast cancer epithelial cells via signaling pathways
- in-vitro, BC, MDA-MB-231
Apoptosis↑, BAX↑, Bcl-2↓, P53↑, PTEN↑, hTERT/TERT↓, p‑ERK↓, cycD1/CCND1↓,
139- Tomatine,  CUR,    Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells
- in-vitro, Pca, PC3
NF-kB↓, Bcl-2↓, p‑Akt↓, p‑ERK↓,
3423- TQ,    Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics
- Review, Var, NA
AntiCan↑, Inflam↓, hepatoP↑, RenoP↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, ROS↑, P53↑, PTEN↑, P21↑, p27↑, BRCA1↑, PI3K↓, Akt↓, MAPK↓, ERK↓, p‑ERK↓, MMPs↓, FAK↓, Twist↓, Zeb1↓, EMT↓, TumMeta↓, angioG↓, VEGF↓, HDAC↓, Maspin↑, SIRT1↑, DNMT1↓, DNMT3A↓, HDAC1↓, HDAC4↓,
2411- UA,    Ursolic acid in health and disease
- Review, Var, NA
Inflam↓, antiOx↑, NF-kB↓, Bcl-xL↓, Bcl-2↓, cycD1/CCND1↓, Ki-67↓, CD31↓, STAT3↓, EGFR↓, P53↑, P21↓, HK2↓, PKM2↓, ATP↓, lactateProd↓, p‑ERK↓, MMP↓, NO↑, ATM↑, Casp3↑, AMPK↑, JNK↑, FAO↑, FASN↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *GSTs↑, neuroP↑,
1817- VitK2,    Research progress on the anticancer effects of vitamin K2
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, TumCI↓, TumCG↓, ChemoSen↓, ChemoSideEff↓, toxicity∅, eff↑, cycD1/CCND1↓, CDK4↓, eff↑, IKKα↓, NF-kB↓, other↑, p27↑, cMyc↓, i-ROS↑, Bcl-2↓, BAX↑, p38↑, MMP↓, Casp9↑, p‑ERK↓, RAS↓, MAPK↓, p‑P53↑, Casp8↑, Casp3↑, cJun↑, MMPs↓, eff↑, eff↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 64

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   Catalase↓, 2,   GSH↓, 1,   HO-1↓, 1,   HO-1↑, 1,   HO-2↓, 1,   lipid-P?, 1,   lipid-P↑, 2,   MDA↑, 1,   NOX4↓, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS↓, 5,   ROS↑, 14,   ROS⇅, 1,   i-ROS↑, 1,   SAM-e↝, 1,   SIRT3↑, 1,   SOD↓, 2,   SOD2↑, 1,   Trx1↑, 1,   TrxR1↓, 1,  

Metal & Cofactor Biology ⓘ

Tf↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 3,   ATP↓, 3,   CDC2↓, 2,   CDC25↓, 2,   MEK↓, 2,   p‑MEK↓, 4,   MKK4↓, 1,   MMP↓, 11,   MPT↑, 1,   mtDam↑, 1,   Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↑, 1,   ACLY↓, 1,   AMPK↓, 1,   AMPK↑, 2,   cMyc↓, 5,   p‑CREB↓, 1,   ECAR↝, 1,   FAO↑, 1,   FASN↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 2,   NAD↝, 1,   PDK1?, 2,   PFK1↓, 1,   PFK2↓, 1,   PI3K/Akt↝, 1,   PKM2↓, 2,   PPARα↓, 1,   PPARγ↑, 1,   p‑S6↓, 1,   SIRT1↓, 1,   SIRT1↑, 2,   SREBP2↓, 1,  

Cell Death ⓘ

Akt↓, 11,   Akt↑, 1,   p‑Akt↓, 19,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 12,   ATF2↓, 1,   BAD↑, 1,   Bak↑, 1,   BAX↑, 14,   Bax:Bcl2↑, 3,   Bcl-2↓, 16,   Bcl-xL↓, 7,   BID↑, 1,   BIM↑, 1,   BMP2↓, 1,   Casp↑, 1,   Casp2↑, 1,   Casp3↓, 1,   Casp3↑, 17,   Casp8↑, 4,   cl‑Casp8↑, 1,   Casp9↑, 11,   proCasp9↓, 1,   cFLIP↓, 1,   p‑Chk2↓, 1,   Cyt‑c↑, 9,   Diablo↑, 4,   DR4↑, 1,   DR5↑, 4,   Fas↑, 1,   GRP58↓, 1,   hTERT/TERT↓, 2,   ICAD↓, 1,   iNOS↓, 4,   JNK↑, 2,   p‑JNK↓, 3,   p‑JNK↑, 5,   MAPK↓, 3,   MAPK↑, 1,   MAPK↝, 1,   p‑MAPK↓, 1,   Mcl-1↓, 5,   MDM2↓, 2,   Myc↓, 2,   Necroptosis↑, 1,   NOXA↑, 1,   p27↑, 3,   p38↓, 4,   p38↑, 1,   p‑p38↓, 5,   p‑p38↑, 4,   PUMA↑, 1,   RIP1↓, 1,   p‑RSK↓, 1,   survivin↓, 5,   Telomerase↓, 1,   TRAIL↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,   SOX9↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   cJun↑, 1,   EZH2↓, 1,   ac‑H3↑, 1,   ac‑H4↑, 1,   other↓, 1,   other↑, 1,   tumCV↓, 7,  

Protein Folding & ER Stress ⓘ

ATF6↑, 1,   CHOP↑, 2,   eIF2α↑, 1,   ER Stress↑, 3,   GRP78/BiP↑, 1,   HSP70/HSPA5↓, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   BNIP3↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair ⓘ

ATM↑, 1,   BRCA1↑, 1,   DNAdam↓, 1,   DNAdam↑, 3,   DNMT1↓, 1,   DNMT3A↓, 1,   DNMTs↓, 1,   P53↑, 9,   p‑P53↑, 1,   cl‑PARP↑, 9,   PARP1↑, 1,   PCNA↓, 3,   SIRT6↑, 1,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   p‑CDK1↓, 1,   CDK2↓, 5,   CDK4↓, 4,   Cyc↓, 1,   cycA1/CCNA1↓, 1,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 14,   cycE/CCNE↓, 2,   P21↓, 3,   P21↑, 4,   p‑RB1↓, 3,   Securin↓, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State ⓘ

BRAF↝, 1,   CD133↓, 1,   CD24↓, 1,   CD44↓, 2,   CDK8↓, 1,   cFos↓, 1,   cMET↓, 3,   p‑cMET↓, 1,   CSCs↓, 3,   EMT↓, 8,   ERK↓, 3,   p‑ERK↓, 53,   FOXM1↓, 1,   FOXO3↑, 1,   GREM1↓, 1,   GSK‐3β↓, 1,   HDAC↓, 2,   HDAC1↓, 1,   HDAC4↓, 1,   IGF-1↓, 1,   IGF-1R↓, 1,   Let-7↑, 1,   LGR5↓, 1,   mTOR↓, 4,   p‑mTOR↓, 1,   NOTCH↓, 2,   p‑P70S6K↓, 1,   p‑P90RSK↑, 1,   PI3K↓, 6,   p‑PI3K↓, 2,   PTEN↑, 5,   PTEN↝, 1,   RAS↓, 1,   Src↓, 1,   STAT3↓, 8,   p‑STAT3↓, 4,   p‑STAT5↓, 1,   TCF↑, 1,   TOP1↓, 1,   TOP2↓, 1,   TOP2↑, 1,   TumCG↓, 5,   Wnt↓, 4,   Wnt/(β-catenin)↓, 2,  

Migration ⓘ

AntiAg↓, 1,   AP-1↓, 1,   Ca+2↑, 2,   Ca+2↝, 1,   cal2↓, 1,   CD31↓, 1,   CLDN2↓, 1,   CXCL12↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 6,   EMMPRIN↓, 1,   F-actin↓, 1,   FAK↓, 4,   p‑FAK↓, 1,   Fibronectin↓, 1,   ITGB1↓, 1,   Ki-67↓, 3,   miR-200b↑, 1,   MMP1↓, 1,   MMP2↓, 12,   MMP7↓, 1,   MMP9↓, 16,   pro‑MMP9↓, 1,   MMPs↓, 4,   N-cadherin↓, 6,   PDGF↓, 1,   PKCδ↓, 2,   p‑PKCδ↓, 1,   RIP3↓, 1,   Slug↓, 2,   p‑SMAD2↓, 3,   SMAD3↓, 1,   p‑SMAD3↓, 2,   SMAD4↓, 1,   Snail↓, 6,   TGF-β↓, 4,   TIMP1↑, 1,   TSP-1↑, 1,   TumCI↓, 7,   TumCMig↓, 10,   TumCP↓, 10,   TumMeta↓, 6,   Twist↓, 6,   uPA↓, 2,   Vim↓, 7,   Zeb1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature ⓘ

angioG↓, 5,   angioS↑, 1,   ATF4↑, 1,   ECM/TCF↓, 1,   EGFR↓, 7,   p‑EGFR↓, 1,   Endoglin↑, 1,   Hif1a↓, 7,   NO↓, 2,   NO↑, 1,   p‑PDGFR-BB↓, 1,   VEGF↓, 13,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 10,   CRP↓, 1,   CXCR4↓, 4,   IFN-γ↓, 1,   IKKα↓, 3,   IL1↓, 2,   IL10↓, 1,   IL1α↓, 2,   IL1β↓, 2,   IL6↓, 6,   Inflam↓, 7,   p‑IκB↓, 1,   JAK↓, 1,   MCP1↓, 1,   MIP2↓, 1,   NF-kB↓, 12,   NF-kB↑, 1,   PD-L1↓, 1,   PGE2↓, 4,   PSA↓, 1,   SOCS1↑, 1,   TNF-α↓, 4,  

Cellular Microenvironment ⓘ

ADAM17↓, 1,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 3,   CDK6↓, 3,   COMT↓, 2,  

Drug Metabolism & Resistance ⓘ

ABCG2↓, 1,   BioAv↓, 1,   BioAv↑, 3,   ChemoSen↓, 1,   ChemoSen↑, 10,   Dose↑, 1,   Dose↝, 3,   Dose∅, 2,   eff↓, 1,   eff↑, 24,   Half-Life↓, 1,   Half-Life↝, 1,   MRP1↓, 1,   RadioS↑, 2,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

AR↓, 3,   ascitic↓, 1,   BRAF↝, 1,   BRCA1↑, 1,   CRP↓, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 7,   p‑EGFR↓, 1,   EZH2↓, 1,   FOXM1↓, 1,   GutMicro↑, 2,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 6,   Ki-67↓, 3,   Maspin↑, 1,   Myc↓, 2,   PD-L1↓, 1,   PSA↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 4,   cardioP↑, 1,   chemoP↑, 2,   ChemoSideEff↓, 1,   ChemoSideEff∅, 1,   hepatoP↑, 2,   neuroP↑, 1,   radioP↑, 2,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 1,   toxicity∅, 1,   TumVol↓, 3,   Weight∅, 1,  
Total Targets: 354

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   Catalase↑, 5,   GPx↑, 1,   GSH↑, 3,   GSR↑, 1,   GSTs↑, 3,   HO-1↑, 2,   lipid-P?, 1,   lipid-P↓, 2,   MDA↓, 2,   NRF2↑, 3,   ROS↓, 11,   SOD↑, 5,  

Mitochondria & Bioenergetics ⓘ

p‑MEK↓, 1,   MMP↑, 3,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cAMP↑, 1,   p‑CREB↑, 1,  

Cell Death ⓘ

Akt↑, 1,   Apoptosis↓, 1,   Casp3↓, 1,   iNOS↓, 3,   p‑JNK↓, 4,   MAPK↓, 3,   MAPK↑, 1,   p‑MAPK↓, 1,   necrosis↓, 1,   p38↓, 2,   p‑p38↓, 4,  

Transcription & Epigenetics ⓘ

p‑cJun↓, 1,   other↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   p‑ERK↓, 11,   PI3K↑, 1,  

Migration ⓘ

5LO↓, 2,   Ca+2↝, 1,   p‑Cofilin↓, 1,   COL1↓, 1,   E-cadherin↑, 1,   heparanase↑, 1,   MMP3↓, 1,   p‑Smad1↑, 1,   SMAD2↓, 1,   SMAD3↓, 1,   p‑SMAD5↑, 1,   TGF-β1↓, 1,   Vim↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   NO↓, 2,   NO↑, 1,  

Barriers & Transport ⓘ

BBB?, 1,   BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

CD25+↓, 1,   CD69↓, 1,   COX1↓, 1,   COX2↓, 3,   CTLA-4↓, 1,   IFN-γ↓, 1,   IKKα↓, 1,   IL17↓, 1,   IL1β↓, 2,   IL2↓, 1,   IL4↓, 2,   IL6↓, 1,   Inflam↓, 6,   Macrophages↓, 1,   Neut↓, 1,   NF-kB↓, 4,   p‑NF-kB↓, 2,   p‑p50↓, 1,   p‑p65↓, 1,   PGE2↓, 1,   PGE2↑, 1,   Th1 response↓, 1,   Th2↑, 2,   TLR4↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission ⓘ

AChE↓, 2,   BChE↓, 1,   BDNF↑, 1,   tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 2,   NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,  

Clinical Biomarkers ⓘ

BMD↑, 1,   EGFR↓, 1,   GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   cardioP↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 6,   Strength↑, 1,   toxicity∅, 2,  
Total Targets: 98

Scientific Paper Hit Count for: ERK, ERK signaling
7 Silymarin (Milk Thistle) silibinin
5 Curcumin
5 Quercetin
3 Apigenin (mainly Parsley)
3 Luteolin
3 Artemisinin
3 Shikonin
2 Boswellia (frankincense)
2 Deguelin
2 Piperine
2 Silver-NanoParticles
1 Allicin (mainly Garlic)
1 alpha Linolenic acid
1 Andrographis
1 Astaxanthin
1 Berbamine
1 Berberine
1 Betulinic acid
1 Boron
1 Citric Acid
1 Photodynamic Therapy
1 Docosahexaenoic Acid
1 Ellagic acid
1 Emodin
1 Paclitaxel
1 Fisetin
1 Gallic acid
1 Grapeseed extract
1 Lycopene
1 Magnolol
1 Magnetic Fields
1 Myricetin
1 Propolis -bee glue
1 SonoDynamic Therapy UltraSound
1 Hyperthermia
1 Piperlongumine
1 EGCG (Epigallocatechin Gallate)
1 Resveratrol
1 Sanguinarine
1 Sulforaphane (mainly Broccoli)
1 Salvia miltiorrhiza
1 Tomatine
1 Thymoquinone
1 Ursolic acid
1 Vitamin K2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:105  State#:1  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page